Schuster SJ - Search Results

1

CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.

Ghilardi G, Williamson S, Pajarillo R, Paruzzo L, Chen L, Grady C, Doucette A, Nemecek E, Gabrielli G, Barta SK, Svoboda J, Chong EA, Yelton R, Nasta SD, Landsburg DJ, Ugwuanyi O, Chen AI, Schachter L, White G, Ballard HJ, Weber E, Curley C, Porter DL, Garfall AL, Hwang WT, Guerra CE, Maziarz RT, Schuster SJ, Ruella M. Ghilardi G, et al. Among authors: schuster sj. NEJM Evid. 2024 Apr;3(4):EVIDoa2300213. doi: 10.1056/EVIDoa2300213. Epub 2024 Mar 26. NEJM Evid. 2024. PMID: 38776868

2

Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation.

Tsai D, Moore H, Hardy C, Porter D, Loh E, Vaughn D, Luger S, Schuster S, Stadtmauer E. Tsai D, et al. Bone Marrow Transplant. 1999 Sep;24(5):521-6. doi: 10.1038/sj.bmt.1701944. Bone Marrow Transplant. 1999. PMID: 10482937

3

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.

Porter DL, Luger SM, Duffy KM, Stadtmauer EA, Laport G, Schuster SJ, Orloff G, Tsai D, McDaid K, Kathakali A, Leonard DG, Antin JH. Porter DL, et al. Among authors: schuster sj. Biol Blood Marrow Transplant. 2001;7(4):230-8. doi: 10.1053/bbmt.2001.v7.pm11349810. Biol Blood Marrow Transplant. 2001. PMID: 11349810 Free article. Clinical Trial.

4

Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.

Cohen AD, Luger SM, Sickles C, Mangan PA, Porter DL, Schuster SJ, Tsai DE, Nasta S, Gewirtz AM, Stadtmauer EA. Cohen AD, et al. Among authors: schuster sj. Bone Marrow Transplant. 2002 Jul;30(1):23-8. doi: 10.1038/sj.bmt.1703602. Bone Marrow Transplant. 2002. PMID: 12105773

5

Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy.

Buckanovich RJ, Liu G, Stricker C, Luger SM, Stadtmauer EA, Schuster SJ, Duffy K, Tsai D, Pruitt A, Porter DL. Buckanovich RJ, et al. Among authors: schuster sj. Ann Hematol. 2002 Jul;81(7):410-3. doi: 10.1007/s00277-002-0481-4. Epub 2002 Jul 12. Ann Hematol. 2002. PMID: 12185517

6

Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation.

Laport GG, Levine BL, Stadtmauer EA, Schuster SJ, Luger SM, Grupp S, Bunin N, Strobl FJ, Cotte J, Zheng Z, Gregson B, Rivers P, Vonderheide RH, Liebowitz DN, Porter DL, June CH. Laport GG, et al. Among authors: schuster sj. Blood. 2003 Sep 15;102(6):2004-13. doi: 10.1182/blood-2003-01-0095. Epub 2003 May 22. Blood. 2003. PMID: 12763934 Free article. Clinical Trial.

7

Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantation.

Gerecitano J, Mathias C, Mick R, Duffy KM, Luger S, Stadtmauer EA, Schuster SJ, Tsai D, Nasta S, Berlin J, Phillips DK, High KA, Porter DL. Gerecitano J, et al. Among authors: schuster sj. J Hematother Stem Cell Res. 2003 Apr;12(2):215-23. doi: 10.1089/152581603321628359. J Hematother Stem Cell Res. 2003. PMID: 12804180

8

Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.

Tsai DE, Maillard I, Schuster SJ, Nasta SD, Porter DL, Klumpp TR, Goldenberg DM, Luger SM, Alavi A, Sharkey RM, Hartzell KB, Stadtmauer EA. Tsai DE, et al. Among authors: schuster sj. Clin Lymphoma. 2003 Jun;4(1):56-9. doi: 10.3816/clm.2003.n.015. Clin Lymphoma. 2003. PMID: 12837157

9

Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenstrom's macroglobulinemia.

Tsai DE, Maillard I, Downs LH, Alavi A, Nasta SD, Glatstein E, Schuster SJ. Tsai DE, et al. Among authors: schuster sj. Leuk Lymphoma. 2004 Mar;45(3):591-5. doi: 10.1080/10428190310001597946. Leuk Lymphoma. 2004. PMID: 15160923

10

Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.

Loren AW, Luger SM, Stadtmauer EA, Tsai DE, Schuster S, Nasta SD, Goldstein SC, Perl A, Orloff G, Oliver JC, Green J, Emerson SG, Porter DL. Loren AW, et al. Bone Marrow Transplant. 2005 May;35(9):921-6. doi: 10.1038/sj.bmt.1704887. Bone Marrow Transplant. 2005. PMID: 15765118

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

269 results

Search Page

Filters